Loading cart...
Noveltreat 0.5 mg Pre-filled Pen (Semaglutide)
Medically reviewed by Sanjay Gangani, B.Pharm, CMO & Pharmacist
| Active Ingredient | Semaglutide |
|---|---|
| Indication | weight loss and maintenance for overweight or obese adults |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| Strength:- | 0.5mg |
| Packaging | 2 Pre-filled Pens in 1 box |
1 / 2
Noveltreat 0.5 mg Pre-filled Pen (Semaglutide) | ||||
|---|---|---|---|---|
| Pack Size | Price | Quantity | Add To Cart | |
| 1 Box (2 Pre Filled Pens) | $72 | |||
| 2 Box (4 Pre Filled Pens) | $135 | |||
| 3 Box (6 Pre Filled Pens) | $180 | |||
What is Noveltreat 0.5 mg
Product identity
| Field | Detail |
| Brand name | Noveltreat |
| Generic name | Semaglutide |
| Strength covered here | 0.5 mg per dose, in 0.5 mL |
| Other strengths marketed | 0.25 mg, 1 mg, 1.7 mg, 2.4 mg |
| Dosage form | Solution for injection, prefilled pen |
| Route | Subcutaneous, under the skin |
| Frequency | Once weekly, same day each week |
| Drug class | GLP-1 receptor agonist |
| Approved Indian use | Chronic weight management in adults |
| Maintenance dose | 2.4 mg once weekly |
| Doses per pack | Two |
| MRP of the 0.5 mg pack | Rs. 1,945 |
| Manufacturer | Sun Pharmaceutical Industries Ltd, India |
| Diabetes brand of same molecule | Sematrinity, from the same company |
| Prescription status | Prescription required |
| Reference label used | US FDA label for semaglutide injection |
How it works (mechanism of action)
Dosage guide
Doses are from the reference label. Your doctor sets yours.
Weekly dose escalation for weight management
| Weeks | Dose once weekly | Purpose of this step |
| 1 to 4 | 0.25 mg | Starting dose, to build tolerance |
| 5 to 8 | 0.5 mg | Second step, the strength in this pack |
| 9 to 12 | 1 mg | Third step |
| 13 to 16 | 1.7 mg | Fourth step, or a maintenance option |
| 17 onward | 2.4 mg | Recommended maintenance dose |
If you miss a dose
| Situation | What the label says |
| Next dose is over 2 days away | Inject the missed dose as soon as possible |
| Next dose is under 2 days away | Skip it and resume on your usual day |
| Two or more doses missed | Resume as scheduled, or restart and re-escalate |
How to take it
Precautions
Absolute contraindications
Conditions to disclose to your doctor
Food and drink precautions
Before-use safety checklist
Side effects
Rates below are from the 2.4 mg maintenance dose against placebo.
Common side effects
| Side effect | On semaglutide | On placebo |
| Nausea | 44% | 16% |
| Diarrhoea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Abdominal pain | 20% | 10% |
| Headache | 14% | 10% |
| Fatigue | 11% | 5% |
| Indigestion | 9% | 3% |
| Dizziness | 8% | 4% |
| Low blood sugar in type 2 diabetes | 6% | 2% |
| Hair loss | 3% | 1% |
| Injection site reaction | 1.4% | 1% |
Less common but serious side effects
| Side effect | Why it matters |
| Acute pancreatitis | The drug is stopped if it is suspected |
| Gallstones or gallbladder disease | Needs assessment and may need surgery |
| Severe low blood sugar | Higher with insulin or sulfonylureas |
| Acute kidney injury | Follows dehydration from vomiting or diarrhoea |
| Worsening diabetic retinopathy | Eyes need monitoring in diabetes |
| Anaphylaxis or angioedema | A medical emergency |
| Sustained faster resting heart rate | May require stopping the drug |
| Lung aspiration under anaesthesia | Tell anaesthetists in advance |
| NAION, sudden vision loss | Very rare, needs the drug stopped |
| Altered skin sensation | 2% at 2.4 mg, and rises with higher doses |
Drug interactions – avoid with
| Drug or group | Why it matters |
| Any other semaglutide product | Do not combine, risk of overdose |
| Any other GLP-1 receptor agonist | Do not combine, labelled limitation |
| Insulin | Serious low blood sugar, dose may need reducing |
| Sulfonylureas | Serious low blood sugar, dose may need reducing |
| Other diabetes medicines | Blood sugar needs closer monitoring |
| Oral medicines in general | Slower stomach emptying may alter absorption |
| Diuretics | Add to dehydration and kidney risk |
| ACE inhibitors and sartans | Add to kidney risk when dehydrated |
| Sedatives for procedures | Aspiration risk, inform the team first |
| Alcohol | Adds to low blood sugar and dehydration |

Reviews
There are no reviews yet.